Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
Asia-Pacific journal of clinical oncology. 2019 Nov [Epub]
Andrew Schmidt, Arun Azad, Jeffrey Goh, Carole Harris, Anthony M Joshua, Andrew Weickhardt, Laurence Krieger
Liz Plummer Cancer Centre, Cairns, Queensland, Australia., Peter McCallum Cancer Centre, Melbourne, Victoria, Australia., Royal Brisbane and Women's Hospital, Butterfield Street, Herston & University of Queensland, St Lucia, Queensland, Australia., St George Hospital and Sutherland Clinical School UNSW, Kogarah, New South Wales, Australia., The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia., Royal North Shore Hospital, Reserve Rd, St Leonards, Northern Cancer Institute, St. Leonards, New South Wales, Australia.